Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Immune Regulation

Immune Regulation
2011 FOUNDED
PRIVATE STATUS
Later Stage VC LATEST DEAL TYPE
$5.51M LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of anti-inflammatory peptides designed to treat immuno-inflammatory diseases resulting from a poorly controlled or overactive immune response. The company's peptides have the ability to significantly advance the control and management of moderate to severe chronic inflammatory diseases, with the potential for diseases modification and remission, enabling patients with immuno-inflammatory diseases like asthma, atopic dermatitis and inflammatory bowel diseases to get better treatment and faster recovery.

Formerly Known As
Peptinnovate
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Stevenage Bioscience Catalyst, Gunnels Wood Road
  • Hertfordshire
  • Stevenage SG1 2FX
  • England, United Kingdom

+44 01438 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Immune Regulation’s full profile, request a free trial.

Immune Regulation Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 01-Jan-2018 $5.51M 000.00 Completed Generating Revenue
4. Later Stage VC 14-Jun-2017 00.000 00.00 Completed Generating Revenue
3. Early Stage VC 28-Jul-2015 00000 00.000 000.00 Completed Generating Revenue
2. Grant $938K Completed Generating Revenue
1. Angel (individual) 17-Dec-2014 $938K $938K 0000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Immune Regulation Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Ordinary 00,000 00.000000 0000.00 0000.00 00 0000.00 0.000
To view this company’s complete Cap Table, request access »

Immune Regulation Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
24Haymarket Angel Group Minority 000 0000 000000 0
NCL Technology Ventures Asset Manager Minority 000 0000 000000 0
Metellus Venture Capital Minority 000 0000 000000 0

Immune Regulation Executive Team (11)

Name Title Board
Seat
Contact
Info
Richard Nagle Chief Executive Officer & Board Member
Clare Burgess Ph.D Chief Operating Officer
Nicky Cooper Ph.D Co-Chief Scientific Officer
Roly Foulkes Ph.D Co-Chief Scientific Officer
David Beadle Chief Business Officer & Board Member

2 Former Executives

You’re viewing 5 of 11 executives. Get the full list »

Immune Regulation Board Members (11)

Name Representing Role Since Contact
Info
Anthony Martin Ph.D Immune Regulation Chairman 000 0000
Ben Cons Immune Regulation Board Member 000 0000
Christopher Smith Immune Regulation Board Member 000 0000
Clive Page Immune Regulation Chairman 000 0000
David Beadle Immune Regulation Chief Business Officer & Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 11 board members. Get the full list »